Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic C
A phase 1/2 trial of Gemcitabine, Paclitaxel / nab-paclitaxel in pancreatic ductal adenocarcinoma, run by Nelum Corp, active and no longer recruiting.
Overview
Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer is a phase 1/2 interventional study registered as NCT04827953 by Nelum Corp, with 28 participants enrolled, started 2021-09-01 and due to reach its primary completion in 2025-04. Interventions recorded: Gemcitabine, Nab paclitaxel, NLM-001, Zalifrelimab. Conditions listed: Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
- TrialStudy of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Shares Gemcitabine, Paclitaxel / nab-paclitaxel, Pancreatic ductal adenocarcinoma.
- TrialA Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
Shares Gemcitabine, Paclitaxel / nab-paclitaxel, Pancreatic ductal adenocarcinoma.
- TrialStudy of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
- TrialIntra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
- TrialEvaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer
- TrialClinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer
- TrialPolymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer